Last 23 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -20.25 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 184.11 | 318.79 | 31352.57 | 2431.30 | 26.61 | 199.55 | 48.81 | 13.51 | 199.58 | 346.73 | 286.82 | 141.70 | 9.09 |
| — | +59.8% | +64133.2% | +17899.0% | -86.7% | -42.4% | -83.0% | -90.5% | +2096.1% | +4213.9% | +31972.9% | +16700.2% | — | |
| P/B Ratio | 5.93 | 5.83 | 5.87 | 4.65 | 2.62 | 3.06 | 3.29 | 4.15 | 4.70 | 4.72 | 3.19 | 2.11 | 0.47 |
| — | +90.6% | +78.4% | +12.0% | -44.3% | -35.2% | +3.0% | +96.7% | +909.2% | +1046.6% | +252.3% | +45.4% | -84.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | 1.72 |
| — | — | — | — | — | — | — | — | — | — | — | — | -97.6% | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
NewAmsterdam Pharma Company N.V.'s operating margin was -1921.7% in Q1 2026, up 204265.8 pp QoQ and up 392.8 pp YoY. The trailing four-quarter average of -56035.3% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 16.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 99.7% | 83.6% | -84.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -16.4% | -184.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | |
| Operating Margin | -1002.9% | -1921.7% | -206187.5% | -15845.7% | -186.1% | -2314.5% | -338.5% | -85.9% | -2306.9% | -3960.2% | -6360.4% | -2474.2% | -509.9% |
| — | +17.0% | -60818.1% | -18349.1% | +91.9% | +41.6% | +94.7% | +96.5% | -352.5% | -676.7% | -11191.4% | -4414.5% | — | |
| Net Margin | -905.7% | -1593.5% | -234134.4% | -20691.1% | -90.7% | -1327.3% | -721.7% | -57.2% | -1711.6% | -6692.9% | -6163.8% | -2230.1% | -691.1% |
| — | -20.1% | -32341.5% | -36083.0% | +94.7% | +80.2% | +88.3% | +97.4% | -147.7% | -868.4% | -10672.0% | -3925.1% | — |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -28.3% | -7.2% | -10.6% | -9.6% | -2.2% | -5.2% | -16.2% | -4.3% | -9.8% | -26.8% | -13.2% | -8.6% | -8.8% |
| — | -39.5% | +34.6% | -120.0% | +77.1% | +80.8% | -22.8% | +49.4% | -10.3% | -119.4% | -172.5% | -125.2% | +58.8% | |
| ROA | -24.9% | -6.5% | -9.6% | -9.0% | -2.1% | -4.7% | -14.1% | -3.8% | -8.3% | -22.4% | -11.5% | -7.7% | -8.0% |
| — | -37.3% | +31.9% | -139.3% | +74.5% | +79.1% | -23.0% | +51.3% | -4.9% | -108.5% | -171.2% | -124.8% | +59.1% | |
| ROIC | -188.2% | -21.8% | -25.8% | -20.4% | -21.9% | -665.4% | — | — | — | — | — | -1304.9% | — |
| — | +96.7% | — | — | — | — | — | — | — | — | — | -3500.6% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 51.1% YoY to 9.76x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q2 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | -93.0% | -49.9% | -72.7% | -71.0% | +380.8% | +184.1% | +548.5% | +395.2% | -64.5% | -74.6% | — | -91.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 7.88 | 9.76 | 7.88 | 12.57 | 21.08 | 19.98 | 8.08 | 10.61 | 9.83 | 8.17 | 6.95 | 10.15 | 13.26 |
| — | -51.1% | -2.5% | +18.4% | +114.5% | +144.6% | +16.2% | +4.5% | -25.8% | -38.4% | -17.0% | +6.2% | +122.5% | |
| Quick Ratio | 7.88 | 9.76 | 7.88 | 12.57 | 21.08 | 19.98 | 8.08 | 10.61 | 9.83 | 8.17 | 6.95 | 10.15 | 13.26 |
| — | -51.1% | -2.5% | +18.4% | +114.5% | +144.6% | +16.2% | +4.5% | -25.8% | -38.4% | -17.0% | +6.2% | +122.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -29.46 | -13.72 | -561.49 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying NAMS stock.
NewAmsterdam Pharma Company N.V.'s current P/E is -20.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
NewAmsterdam Pharma Company N.V.'s current operating margin is -1002.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking NewAmsterdam Pharma Company N.V.'s business trajectory between earnings reports.